(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally...
Stats | |
---|---|
Šios dienos apimtis | 1.42M |
Vidutinė apimtis | 3.35M |
Rinkos kapitalizacija | 162.89B |
EPS | ¥0 ( 2024-01-31 ) |
Kita pelno data | ( ¥-323.99 ) 2024-05-13 |
Last Dividend | ¥7.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | -0.940 |
ATR14 | ¥0.448 (0.11%) |
Tūris Koreliacija
Sumitomo Pharma Co., Ltd. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Sumitomo Pharma Co., Ltd. Koreliacija - Valiuta/Žaliavos
Sumitomo Pharma Co., Ltd. Finansinės ataskaitos
Annual | 2022 |
Pajamos: | ¥555.54B |
Bruto pelnas: | ¥376.63B (67.79 %) |
EPS: | ¥-187.55 |
FY | 2022 |
Pajamos: | ¥555.54B |
Bruto pelnas: | ¥376.63B (67.79 %) |
EPS: | ¥-187.55 |
FY | 2022 |
Pajamos: | ¥560.04B |
Bruto pelnas: | ¥402.91B (71.94 %) |
EPS: | ¥102.19 |
FY | 2021 |
Pajamos: | ¥515.95B |
Bruto pelnas: | ¥378.18B (73.30 %) |
EPS: | ¥141.50 |
Financial Reports:
No articles found.
Sumitomo Pharma Co., Ltd. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥14.00 (N/A) |
¥0 (N/A) |
¥7.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥4.75 | 2000-03-28 |
Last Dividend | ¥7.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 47 | -- |
Total Paid Out | ¥382.25 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.47 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
6638.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
5965.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
4662.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
3902.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
3134.T | Ex Dividend Junior | 2024-04-26 | Annually | 0 | 0.00% | |
2004.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8999.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
8550.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7872.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
7013.T | No Dividend Player | 2023-09-28 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.526 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.164 | 1.200 | -5.46 | -6.56 | [0 - 0.3] |
returnOnEquityTTM | -0.440 | 1.500 | -6.00 | -9.00 | [0.1 - 1] |
payoutRatioTTM | -0.0161 | -1.000 | -0.161 | 0.161 | [0 - 1] |
currentRatioTTM | 0.627 | 0.800 | -1.864 | -1.491 | [1 - 3] |
quickRatioTTM | 0.333 | 0.800 | -2.75 | -2.20 | [0.8 - 2.5] |
cashRatioTTM | 0.0866 | 1.500 | -0.630 | -0.945 | [0.2 - 2] |
debtRatioTTM | 0.389 | -1.500 | 3.52 | -5.29 | [0 - 0.6] |
interestCoverageTTM | -8.87 | 1.000 | -4.40 | -4.40 | [3 - 30] |
operatingCashFlowPerShareTTM | -693.01 | 2.00 | -10.00 | -10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -728.72 | 2.00 | -10.00 | -10.00 | [0 - 20] |
debtEquityRatioTTM | 1.199 | -1.500 | 5.20 | -7.81 | [0 - 2.5] |
grossProfitMarginTTM | 0.599 | 1.000 | 3.34 | 3.34 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.536 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.669 | 1.000 | -4.83 | -4.83 | [0.2 - 2] |
assetTurnoverTTM | 0.312 | 0.800 | -1.256 | -1.005 | [0.5 - 2] |
Total Score | -5.81 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.938 | 1.000 | -0.196 | 0 | [1 - 100] |
returnOnEquityTTM | -0.440 | 2.50 | -3.86 | -9.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -728.72 | 2.00 | -10.00 | -10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -693.01 | 2.00 | -10.00 | -10.00 | [0 - 30] |
payoutRatioTTM | -0.0161 | 1.500 | -0.161 | 0.161 | [0 - 1] |
pegRatioTTM | -2.71 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.834 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -5.01 |
Sumitomo Pharma Co., Ltd.
Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastrointestinal; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. It also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.